FDA does not set a single caffeine cap for dietary supplements. The rules sit across multiple statutes and regulations – the Dietary Supplement Health and Education Act (DSHEA), 21 CFR Part 182, the FD&C Act’s adulteration provisions, and FDA’s guidance on highly concentrated caffeine products. For supplement manufacturers, the real compliance risk is not “how many milligrams,” but product format, concentration, source disclosure, labeling, and FDA’s case-by-case enforcement posture.
FDA has stated publicly that 400 mg of caffeine per day is “not generally associated with negative effects” for healthy adults. That figure comes from FDA’s consumer education materials, not from a binding regulation. It does not give a supplement brand a defense against an adulteration finding, a warning letter, or a recall if the product format, dose, or label presentation raises a public health concern.
This guide covers what every dietary supplement manufacturer should know about FDA’s caffeine framework: what regulations apply, how caffeine is classified as a dietary ingredient, which labeling rules govern Supplement Facts disclosure, where pure and highly concentrated caffeine triggers enforcement, and what compliance steps reduce warning letter and recall risk.
Direct answer for supplement brands
FDA does not enforce a per-serving caffeine cap on dietary supplements. FDA’s 400 mg/day reference is for adult consumers, not a manufacturing standard. The binding limits live in DSHEA’s New Dietary Ingredient (NDI) requirements, Supplement Facts labeling rules, and the FD&C Act § 342 adulteration provisions. Pure and highly concentrated caffeine in bulk form for direct consumer sale is the format FDA has flagged for enforcement.
Does FDA Set a Caffeine Limit for Dietary Supplements?
No, FDA does not publish a numerical caffeine ceiling that every dietary supplement must stay under. The agency regulates caffeine through several different mechanisms depending on the product category, and a supplement’s exposure shifts with each one.
The closest FDA comes to a numerical reference is the 400 mg per day figure cited in consumer education content. That number applies to healthy adults consuming caffeine from any combined source. It is not a compliance threshold for a single product, and it does not protect a brand whose product delivers a dose, concentration, or format FDA views as unsafe.
For dietary supplements specifically, the binding obligations sit in DSHEA (21 USC § 321(ff)), the NDI notification requirements at 21 USC § 350b, the labeling rules at 21 CFR Part 101 Subpart F, and the adulteration provisions of FD&C Act § 342. A caffeine supplement that complies with each of these has reduced its enforcement exposure – but no per-serving “safe harbor” milligram figure exists in regulation.
How 21 CFR 182.1180 Applies to Caffeine
21 CFR § 182.1180 lists caffeine as a substance Generally Recognized as Safe (GRAS) for use in cola-type beverages at concentrations up to 0.02 percent. The regulation is product-specific. It does not extend an automatic GRAS determination to dietary supplements, energy shots, gummies, capsules, or pre-workout powders.
Some supplement brands cite 21 CFR § 182.1180 in their compliance documentation as if it covers all caffeine uses. It does not. A supplement manufacturer cannot point to a cola-type beverage GRAS listing to justify a 300 mg caffeine pre-workout serving. The applicable framework is DSHEA, not 21 CFR Part 182.
The practical takeaway: confirm the regulatory basis your formulation actually relies on. If caffeine in the product is a dietary ingredient under DSHEA, GRAS status under 21 CFR Part 182 is irrelevant. If caffeine is being added to a conventional food product (a beverage, a bar, a confection), then the GRAS framework and the cola-type beverage limit are the governing reference.
Caffeine as an Old Dietary Ingredient vs. New Dietary Ingredient
Under DSHEA, every dietary ingredient is either an “old dietary ingredient” (ODI) sold in the United States before October 15, 1994, or a “new dietary ingredient” (NDI) introduced after that date. NDIs trigger a pre-market notification requirement under 21 USC § 350b. Caffeine itself was widely marketed as a dietary ingredient before 1994 and is generally treated as an ODI in its standard form.
That ODI status does not transfer automatically to every product format. A highly concentrated caffeine extract, a novel delivery system (a transdermal patch, a sublingual film, a sustained-release matrix), or a chemically modified caffeine analog can be a new dietary ingredient even when the active substance is caffeine. FDA has used this analysis to support enforcement against brands selling products that the agency views as having moved beyond the ODI baseline.
For background on how FDA approaches the ODI / NDI line and the recurring agency efforts to publish an authoritative list of grandfathered ingredients, see our deeper read on grandfathered dietary ingredients under DSHEA.
Highly Concentrated Caffeine in Dietary Supplements
FDA’s April 2018 Guidance for Industry, “Highly Concentrated Caffeine in Dietary Supplements,” is the agency’s clearest statement of enforcement posture on bulk caffeine products. The guidance identifies pure or highly concentrated caffeine sold directly to consumers in powder or liquid form as a category that FDA generally considers adulterated under FD&C Act § 342(f)(1)(A).
The rationale is dose-control risk. A single teaspoon of pure powdered caffeine contains approximately 3,200 mg – roughly 28 times the caffeine in an 8-ounce cup of coffee, and a dose at or near published lethal thresholds for some adults. FDA’s view is that consumers cannot reliably measure safe portions from bulk powder using ordinary kitchen tools.
The guidance does not ban caffeine as a dietary ingredient. It targets a specific format: bulk pure or highly concentrated caffeine sold for direct consumer use. Pre-measured capsules, tablets, and finished dosage forms that deliver caffeine at controlled per-serving amounts remain available, provided they meet DSHEA, labeling, and cGMP requirements.
Supplement Facts Labeling Rules for Caffeine
Caffeine in a dietary supplement must appear in the Supplement Facts panel under 21 CFR § 101.36 with the amount per serving disclosed. This applies whether the caffeine is added in isolated form or contributed by herbal ingredients such as guarana, green tea extract, or yerba mate. FDA has issued warning letters specifically for failure to disclose added caffeine amounts on the Supplement Facts panel.
Source disclosure matters. A product that contains both added caffeine and an herbal source of caffeine should state the combined per-serving amount. A product that lists “proprietary blend” without identifying caffeine content can be cited for misbranding under FD&C Act § 343, particularly where the consumer cannot determine the total caffeine load.
For the broader labeling framework that surrounds caffeine disclosure – claims discipline, ingredient declarations, allergen statements, and the FDA-versus-USDA jurisdictional split – see our pillar guide on food labeling laws, requirements, and enforcement risks.
On warning label language, FDA does not prescribe a fixed caffeine warning text for dietary supplements. Some manufacturers voluntarily add cautionary statements such as “Contains caffeine. Not for use by children, pregnant or breastfeeding women, or persons sensitive to the effects of caffeine.” Voluntary warnings can reduce product liability exposure and signal good manufacturing practice, but they do not replace the affirmative Supplement Facts disclosure requirement.
How FDA Caffeine Rules Differ Across Product Categories
FDA regulates caffeine differently depending on whether the product is a conventional food, a dietary supplement, or an over-the-counter (OTC) drug. The same active substance carries different obligations under each framework.
| Product category | Governing framework | Key constraint |
|---|---|---|
| Cola-type beverages | 21 CFR § 182.1180 (GRAS) | Caffeine GRAS at up to 0.02 percent (200 ppm) |
| Conventional foods (non-cola) | FD&C Act § 342 (adulteration), GRAS analysis case by case | No fixed cap; safe-use determination is fact-specific |
| Dietary supplements | DSHEA (21 USC § 321(ff)), NDI rules (21 USC § 350b), Supplement Facts (21 CFR § 101.36) | No fixed cap; ODI / NDI status + format + labeling disclosure determine exposure |
| OTC stimulant drug products | FDA OTC monograph for stimulant drug products (21 CFR Part 340) | Specific labeling and concentration requirements per the monograph |
| Pure / highly concentrated caffeine sold in bulk to consumers | FD&C Act § 342(f)(1)(A); FDA 2018 Guidance for Industry | Generally adulterated as marketed; enforcement priority category |
For dietary supplement brands, this table is the right starting place when a product team asks “where does caffeine sit for us.” The answer is rarely “21 CFR § 182.1180.” It is almost always DSHEA, with the highly concentrated caffeine guidance as the high-risk perimeter.
FDA Caffeine Warning Letters and Enforcement History
FDA’s most visible caffeine enforcement actions came in 2014 and 2015, when the agency issued warning letters to multiple distributors of pure powdered caffeine following deaths linked to consumer overdoses. The targets included Smartpowders, PureBulk, Kreativ Health Inc., Hard Eight Nutrition LLC, and Bridge City LLC. Each letter cited the adulteration provisions of FD&C Act § 342(f)(1)(A) and noted the dose-control failure inherent in selling bulk pure caffeine to retail consumers.
Since then, FDA’s enforcement posture has continued to focus on three patterns: bulk pure caffeine for direct consumer sale, products with undisclosed or misrepresented caffeine content, and products that combine caffeine with other stimulants in doses the agency views as unsafe. Warning letters in this category have also flagged unapproved structure-function claims, missing Supplement Facts disclosures, and cGMP violations identified during inspection.
Brands that receive an FDA Form 483 or a warning letter touching caffeine have a tight response window – typically 15 working days for written response to a warning letter. The response should address every observation, document corrective action, and where appropriate, work with FDA compliance counsel to scope the broader inspection follow-up. For the recurring patterns that lead to these letters, see our deeper read on FDA compliance mistakes that trigger warning letters and enforcement actions.
Compliance Steps for Dietary Supplement Manufacturers
The following checklist is what a supplement compliance officer should run through before scaling a caffeine-containing product, expanding into a new format, or responding to an FDA inquiry.
- Confirm dietary ingredient status. Document whether the caffeine in the product is an old dietary ingredient or a new dietary ingredient under DSHEA. Pay particular attention to concentration, source, and delivery format.
- File NDI notifications when triggered. If the form, concentration, or chemical profile moves the ingredient beyond ODI status, file a New Dietary Ingredient notification at least 75 days before introducing the product into commerce.
- Audit the Supplement Facts panel. Verify that per-serving caffeine content from all sources (added caffeine and herbal contributors) is disclosed. Address proprietary blend language that obscures total caffeine load.
- Review warning and cautionary statements. Add caffeine-specific cautionary language for sensitive populations even where not strictly required. Confirm that the label avoids unapproved disease claims.
- Maintain cGMP records under 21 CFR Part 111. Document specifications, batch records, identity testing, and finished-product testing for caffeine content. Inspectors review this routinely.
- Build a warning letter and recall response plan. Have counsel pre-identified, document templates ready, and a decision tree for voluntary recall versus mandatory FDA-directed recall under FSMA.
For a broader walk-through of how these obligations fit inside the larger FDA framework, see our pillar guide on FDA compliance for food and supplement companies. For a deeper read on FDA’s view of where these obligations break down most often, the related discussion on FDA compliance counsel for manufacturers covers the high-stakes failure modes in more detail.
Frequently Asked Questions
What is the FDA caffeine limit for dietary supplements?
FDA does not publish a per-serving caffeine cap for dietary supplements. The agency’s 400 mg per day reference is a consumer-facing safety guideline, not a manufacturing limit. The binding rules are the DSHEA framework, the NDI notification requirements at 21 USC § 350b, Supplement Facts labeling at 21 CFR § 101.36, and the FD&C Act § 342 adulteration provisions. Concentration, format, and labeling drive enforcement exposure more than any single milligram figure.
Is caffeine an old dietary ingredient or a new dietary ingredient?
Caffeine as a generic dietary ingredient is treated as an old dietary ingredient under DSHEA because it was widely marketed as a supplement before October 15, 1994. That status does not automatically extend to every product format. Highly concentrated extracts, novel delivery systems, and chemically modified caffeine analogs can be new dietary ingredients that trigger the 75-day NDI notification under 21 USC § 350b.
What does 21 CFR 182.1180 say about caffeine?
21 CFR § 182.1180 lists caffeine as Generally Recognized as Safe for use in cola-type beverages at concentrations up to 0.02 percent. The regulation is specific to that product category and does not authorize caffeine use in dietary supplements, pre-workout powders, or energy shots. Supplement manufacturers should not rely on this GRAS listing as the regulatory basis for their formulation.
How does FDA treat pure or highly concentrated caffeine powder?
FDA’s April 2018 Guidance for Industry identifies pure or highly concentrated caffeine sold directly to consumers in bulk powder or liquid form as a category the agency generally considers adulterated under FD&C Act § 342(f)(1)(A). The concern is dose-control risk: a single teaspoon of pure caffeine powder contains roughly 3,200 mg, far above safe single-dose levels for most adults. Pre-measured finished dosage forms are not subject to the same enforcement posture.
Are supplement brands required to list the exact caffeine amount on the label?
Yes. Under 21 CFR § 101.36, the Supplement Facts panel must disclose the per-serving amount of caffeine. This applies to added caffeine and to caffeine contributed by herbal ingredients such as guarana, green tea extract, or yerba mate. Hiding caffeine inside a proprietary blend without identifying the total per-serving amount can support a misbranding citation under FD&C Act § 343.
What should a brand do after receiving an FDA caffeine warning letter?
A warning letter typically requires a written response within 15 working days. The response should address every cited violation, document corrective and preventive actions, and identify a timeline for remediation. Engage FDA compliance counsel early to scope the broader inspection follow-up, evaluate recall obligations under FSMA, preserve documents for any related litigation, and coordinate communications with FDA’s district office and the Office of Dietary Supplement Programs.
The FDA caffeine framework rewards manufacturers who treat the rules as a system rather than a single number. Brands that document ODI status, file NDI notifications when triggered, disclose total per-serving caffeine, avoid bulk pure-caffeine consumer formats, and maintain cGMP records under 21 CFR Part 111 reduce both warning letter exposure and recall risk.
For dietary supplement companies facing FDA scrutiny on a caffeine-containing product, the cost of an experienced regulatory response is small compared to the cost of a recall, an injunction, or a False Claims Act exposure. Early engagement with FDA compliance counsel is the most reliable way to convert an inspection or a warning letter into a manageable outcome.
This article is for informational purposes only and does not constitute legal advice. Consult a qualified attorney about your specific situation. For questions about FDA caffeine regulation, dietary supplement compliance, NDI notifications, or warning letter response, contact the OFW Law team.
Caffeine Compliance Question? Talk to FDA Counsel.
OFW Law’s FDA practice represents dietary supplement manufacturers on NDI notifications, labeling defense, warning letter response, and recall management. Mason Weeda, Managing Principal and FDA Food Practice Head, leads our caffeine and stimulant supplement engagements.
